52 results about "M. pneumoniae" patented technology

The invention relates to the technical field of biology, in particular to a primer probe combination and a detection kit for detecting mycoplasma pneumoniae, chlamydia pneumoniae and adenovirus. The primer probe combination comprises a specific primer pair of mycoplasma pneumoniae shown in SEQ ID NO: 1-2, a specific probe of mycoplasma pneumoniae shown in SEQ ID NO:3, a specific primer pair of chlamydia pneumoniae shown in SEQ ID NO: 4-5, a specific probe of chlamydia pneumoniae shown in SEQ ID NO:6, a specific primer pair of adenovirus shown in SEQ ID NO: 7-8 and a specific probe of adenovirus shown in SEQ ID NO: 9. The primers and the probes have good specificity, and rapid, accurate and sensitive identification of MP, CP and ADV can be achieved in combination with a real time PCR detection method.

The invention relates to a SERS-immunochromatography detection method for rapidly and highly sensitively detecting Mycoplasma pneumoniae infection. The detection principle is that Nitrocellulose membranes (NC) are used as a carrier, a double-layer dye 5,5'-dithiobis (2-nitrobenzoic acid){5,5'-dithiobis- (2-nitrozoic acid), DTNB} labeled Au@Ag nano material coupling detection antibody is used as anSERS probe, a novel surface enhanced Raman spectroscopy (SERS-ICA)-based immunochromatography technology is established by combining the traditional Immunochromatography assay (ICA), and the technology is used for detecting human IgM and Mycoplasma pneumoniae (MP) specific IgM positive serum samples. The detection comprises the processes of sample dilution, SERS probe release, antigen-antibody reaction, result analysis and the like. The SERS-immunochromatography detection method for rapidly and highly sensitively detecting Mycoplasma pneumoniae infection can improve the detection sensitivityof human IgM and the detection rate of the lung branch positive serum specimen, and has important significance for clinical treatment.

The invention relates to a CRISPR (clustered regularly interspaced short palindromic repeat) detection primer group for mycoplasma pneumoniae and an application of the CRISPR detection primer group, and belongs to the technical field of gene detection of a CRISPR technology. The primer group comprises an amplification primer pair and crRNA (CRISPR-derived ribonucleic acid), wherein the amplification primer pair is used for amplifying a sequence shown as SEQ ID NO. (sequence identifier number) 1 of the mycoplasma pneumoniae; crRNA comprises an anchor sequence and a guide sequence; the anchor sequence specifically identifies a Cas protein; and the guide sequence is matched with a target sequence segment in the sequence of SEQ ID NO. 1. The primer group detects the mycoplasma pneumoniae through the CRISPR technology; the detection time of the mycoplasma pneumoniae is shortened; and the detection can be accomplished within 60min. A specific sequence combination obtained by screening acts as the primer group for detection, the primer group has the advantages of high sensitivity and strong specificity, and a limit of detection of the primer group can reach 30 copies. The primer group isused for the CRISPR detection of the mycoplasma pneumoniae, is independent of a complicated variable temperature amplification instrument such as a qPCR (quantitative polymerase chain reaction) instrument, and a CRISPR-Cas technology has wide application prospects in instant diagnosis of the mycoplasma pneumoniae.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

The invention relates to a mycoplasma pneumoniae recombinant antigen and application thereof. The mycoplasma pneumoniae recombinant antigen comprises a PIA fragment, a first binding peptide, a PIB fragment, a second binding peptide and a P30 fragment. Experiment results show that the recombinant antigen can obtain different types of antigen dominant epitopes after being purified in different ways,and the various types of antigen dominant epitopes are stable in expression, namely the different types of antigen dominant epitopes can be stably expressed as required. The matching and screening works of the antigen can be greatly reduced during detection; the detection rate is high, and the specificity is high during the detection of mycoplasma pneumoniae.

The invention relates to the field of in-vitro diagnostic immunoassay, and in particular provides a mycoplasma pneumoniae antigen as well as a preparation method and application thereof. The mycoplasma pneumoniae antigen provided by the invention is protein composed of an antigenic protein sequence P1M:residues 1340-1518, specifically an amino acid sequence shown in SEQ ID NO.1, or protein which is obtained by performing substitution and/or deletion and/or addition on the amino acid sequence shown in the SEQ ID NO.1 by one or more amino acid residues and has same function. The antigen is verified by an immunoserological detection technology to have strong specificity and high sensitivity, and the antigen is easy to culture and purify, is more conducive to industrial production and saves costs; and in addition, the antigen is suitable for preparation of MP antibody detection products, can be used for any forms of products in the field of in-vitro immunodiagnosis, and has broad market prospects.

According to the invention, an SD rat model infected by mycoplasma pneumoniae is adopted for experiments, and it is found that minor radix buplenri granules can remove excessive free radicals caused by mycoplasma pneumoniae infection. In particular, through combination of the minor radix buplenri granules and chloroquine phosphate, the levels of glutathione peroxidase, superoxide dismutase and catalase in serum can be obviously increased, and the content of malondialdehyde can be reduced, so that combined administration can improve the free radical removing capability of an organism and reducecytotoxicity generated by free radical accumulation. The minor radix buplenri granules combined chloroquine phosphate tablets have a purpose of removing excessive free radicals caused by mycoplasma pneumoniae infection, solve the problem of excessive free radicals in mycoplasma pneumoniae infection, have a better sensitization effect on azithromycin, and thus can be used for preventing and treating mycoplasma pneumoniae.

The invention provides a mycoplasma pneumoniae fusion antigen as well as a preparation method and application thereof, and relates to the technical field of biology. The mycoplasma pneumoniae fusion antigen is a fusion protein containing a P1M antigen fragment and a P30A antigen fragment. The mycoplasma pneumoniae fusion antigen provided by the invention is verified by an immunoserological detection technology, and compared with an existing mycoplasma pneumoniae antigen, the mycoplasma pneumoniae fusion antigen is stronger in specificity, higher in sensitivity, easy to culture and purify, morebeneficial to industrial production and lower in cost. The mycoplasma pneumoniae fusion antigen is suitable for preparation of MP antibody detection products, can be processed into products in any form in the field of in-vitro immunodiagnosis, and has a wide market prospect.

The invention discloses a Mycoplasma pneumoniae antigen and its application in simultaneous quantitative detection of Mycoplasma pneumoniae IgG and IgM content in peripheral blood. The amino acid sequence of the mutant Mycoplasma pneumoniae antigen P80 of the invention is as shown in SEQ ID NO.1. The immunoreactivity of the Mycoplasma pneumoniae antigen p80 and the antibody is about 34.6% higher than that of the natural antigen. By combining the Mycoplasma pneumoniae antigen P80 with the quantum dot immunochromatography technology, the shortcoming that existing detection methods of Mycoplasmapneumoniae antibody, such as immunochromatography assay (ICA) and enzyme-linked immunosorbent assay (ELISA), can only detect qualitatively or semi-quantitatively, and the MP-IgM and MP-IgG detection must be carried out twice is solved; and the detection of MP-IgM and MP-IgG can be realized at the same time, so as to distinguish the patients with recent infection or previous infection and reduce the misdiagnosis rate.

The invention belongs to the field of molecular biological detection. Specifically, the invention belongs to the field of detection of pathogens causing respiratory tract infection; and more specifically, the present invention can simultaneously detect influenza A virus, influenza B virus, rhinovirus, respiratory adenovirus, respiratory syncytial virus, and mycoplasma pneumoniae. By using a composition provided by the invention, the six pathogens causing respiratory tract infection can be detected at the same time, and specific infection of one or more pathogens can be identified. Meanwhile, the detection rate is higher than that of the existing composition, and the detection is more accurate.

The invention belongs to the field of medical detection equipment, and provides a combined device for synchronously detecting IgM antibodies of influenza A and B viruses and chlamydia pneumoniae and mycoplasma pneumoniae. The device comprises a double-channel clamping shell, a test strip FluA & B and a test strip CP & MP which are arranged in the double-channel clamping shell in parallel; influenza virus A detection lines arranged on a nitrocellulose membrane of the test strip FluA & B at intervals are coated with high-specificity influenza virus A antigens, influenza virus B detection linesare coated with high-specificity influenza virus B antigens, and first quality control lines are coated with quality control line coating receptors; chlamydia pneumoniae detection lines (CP) arranged on a nitrocellulose membrane of the test strip CP & MP at intervals are coated with high-specificity chlamydia pneumoniae antigens, mycoplasma pneumoniae detection lines (MP) are coated with high-specificity mycoplasma pneumoniae antigens, and second quality control lines are coated with quality control line coating receptors.

The invention discloses a loop-mediated isothermal amplification primer group for detecting mycoplasma pneumoniae. The loop-mediated isothermal amplification primer group is composed of the following three pairs of primers: MP2-F3 and MP2-B3, MP2-FIP and MP2-BIP, and MP2-LF and MP2-LP, wherein the nucleotide sequence of the MP2-F3 is shown as SEQ ID No. 1, the nucleotide sequence of the MP2-B3 is shown as SEQ ID No. 2, the nucleotide sequence of the MP2-FIP is shown as SEQ ID No. 3, the nucleotide sequence of the MP2-BIP is shown as SEQ ID No. 4, the nucleotide sequence of the MP2-LF is shown as SEQ ID No. 5, and the nucleotide sequence of the MP2-LP is shown as SEQ ID No. 6. The primer group provided by the invention can significantly improve detection efficiency, shortens detection time to be within 30 minutes, a decrease by a half compared with 60 minutes or more needed in existing loop-mediated isothermal amplification methods, can be used for rapid detection of mycoplasma pneumoniae infection, provides powerful help for clinical early diagnosis and treatment, and buys time for timely isolation of infectors and control of infection diffusion.

The invention discloses a mycoplasma pneumoniae drug sensitivity rapid detection kit and a preparation method thereof. The kit comprises mycoplasma pneumoniae culture solution, a drug sensitive plate and a drug for treating mycoplasma pneumoniae; the mycoplasma pneumoniae culture solution comprises the following components: 7 to 10 g of agar powder, 5 to 8 g of peptone, 2 to 3 g of short-chain peptide, 700 to 800 mg of morroniside, 3 to 5 g of yeast powder, 2 to 4 g of glucose, 2.5 to 3.5 g of sodium pyruvate, 90 to 120 mL of MEM culture medium, 2 mL of 1% (w/v) phenol red solution, 140 to 180 mL of horse serum, 300 thousand units of penicillin and 750 to 850 mL of distilled water; and the short-chain peptide is composed of 3 to 5 amino acid residues. The kit is stable in performance and high in specificity, and can accurately detect which antibiotic in various clinically common antibiotics is sensitive to a patient when the patient is infected with mycoplasma pneumoniae, so that medication is accurately guided, blind medication and excessive medication are avoided, and the recovery rate is increased.

The invention belongs to the technical field of medicines, and particularly relates to an aryl or heteroaryl substituted thiadiazole compound, a preparation method and application thereof as an antibacterial drug. The compound is represented by formula (1), wherein Ar represents a substituted or unsubstituted aryl group or heteroaryl group. The aryl or heteroaryl substituted thiadiazole compound provided by the invention is a compound with a new structure, and the series of compounds have a relatively strong inhibition effect on gram-positive bacteria and mycoplasma like staphylococcus aureus,staphylococcus epidermidis, enterococcus and clostridium difficile, especially drug-resistant gram-positive bacteria (MRSA, MRSE and VRE); certain inhibition is achieved on macrolide drug-resistant mycoplasma pneumoniae, intragastric administration has a good protection effect on systemic infection mice caused by MRSA intraperitoneal injection, and the compound is worthy of further research and development.